Earnings summaries and quarterly performance for C4 Therapeutics.
Executive leadership at C4 Therapeutics.
Andrew J. Hirsch
Detailed
President and Chief Executive Officer
CEO
JS
Jolie Siegel
Detailed
Chief Legal Officer and Secretary
KS
Kelly Schick
Detailed
Chief People Officer
KA
Kendra Adams
Detailed
Chief Financial Officer and Treasurer
LR
Leonard Reyno
Detailed
Chief Medical Officer
PM
Paige Mahaney
Detailed
Chief Scientific Officer
SB
Scott Boyle
Detailed
Chief Business Officer
Board of directors at C4 Therapeutics.
DG
Donna Grogan, M.D.
Detailed
Director
KC
Kenneth C. Anderson, M.D.
Detailed
Director
LB
Laura Bessen, M.D.
Detailed
Director
OH
Owen Hughes
Detailed
Director
RH
Ronald Harold Wilfred Cooper
Detailed
Chairman of the Board of Directors
SF
Stephen Fawell, Ph.D.
Detailed
Director
SH
Steven Hoerter
Detailed
Director
UK
Utpal Koppikar
Detailed
Director
Research analysts covering C4 Therapeutics.
Recent press releases and 8-K filings for CCCC.
C4 Therapeutics Reports Q4 and Full Year 2025 Financial Results and Business Highlights
CCCC
Earnings
Guidance Update
New Projects/Investments
- C4 Therapeutics reported total revenue of $11.0 million for the fourth quarter of 2025 and $35.9 million for the full year 2025. The net loss was $20.5 million for Q4 2025 and $105.0 million for the full year 2025.
- As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $297.1 million, which is expected to fund operating plans to the end of 2028. This cash position was supported by $125 million in gross proceeds from an equity offering in October 2025.
- The company advanced its clinical programs, including dosing the first patient in the Phase 2 MOMENTUM trial for cemsidomide in February 2026 and planning to initiate a Phase 1b trial of cemsidomide in combination with elranatamab in Q2 2026.
- C4T earned a $2 million milestone payment from Biogen in January 2026 as BIIB145, a degrader designed by C4T, entered clinical development.
2 days ago
C4 Therapeutics Outlines Clinical Pipeline Progress and Financial Runway
CCCC
Product Launch
New Projects/Investments
Guidance Update
- C4 Therapeutics is advancing two clinical degraders: cemsidomide for Multiple Myeloma (MM) and CFT8919 for Non-Small Cell Lung Cancer (NSCLC).
- The company's discovery strategy is now focused on Inflammation, Neuroinflammation, and Neurodegeneration (INN) diseases.
- Cemsidomide, an IKZF1/3 degrader, demonstrated a 53% Overall Response Rate (ORR) at its highest dose level in a Phase 1 trial for heavily pre-treated MM patients, supporting its potential as a best-in-class degrader.
- C4 Therapeutics expects its cash runway to extend to the end of 2028.
- Key upcoming milestones include initiating the Phase 2 MOMENTUM trial in Q1 2026 and the Phase 1b trial with elranatamab in Q2 2026, with a New Drug Application (NDA) submission for cemsidomide by year-end 2028.
3 days ago
C4 Therapeutics Provides Update on Cemsidomide Clinical Development and Financial Runway
CCCC
New Projects/Investments
- C4 Therapeutics (CCCC) is advancing its lead program, cemsidomide, an IKZF1/3 degrader, into later-stage clinical development with a Phase II MOMENTUM trial starting this quarter and a Phase IB combination study with elranatamab (partnered with Pfizer) commencing in Q2.
- The company secured financing in Fall 2025, extending its cash runway to the end of 2028, with potential for over $200 million in additional funding to support Phase III planning.
- C4 Therapeutics is strategically leveraging the FDA's new draft guidance on MRD negativity as a surrogate endpoint for myeloma, integrating it into its clinical trials to potentially expedite accelerated and full approval pathways for cemsidomide.
- The Phase II MOMENTUM trial aims to enroll patients within 12 months, targeting at least a 40% response rate for accelerated approval, with full regulatory endpoint data expected into 2028.
Feb 11, 2026, 4:30 PM
C4 Therapeutics Provides Update on Clinical Pipeline and Financial Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics is advancing its lead program, cemsidomide, an IKZF1/3 degrader, into later-stage clinical development with a Phase 2 MOMENTUM trial starting in Q1 2026 and a Phase 1/b combination study with elranatamab (Pfizer) beginning in Q2 2026.
- The company's recent financing in Fall 2025 extended its cash runway to the end of 2028, with potential for over $200 million in additional funding from warrants to support future Phase 3 planning.
- C4 Therapeutics is leveraging the FDA's new draft guidance on MRD negativity as a potential surrogate endpoint to expedite development and support accelerated approval for cemsidomide, particularly in its MOMENTUM trial and the combination study.
- In its first-in-human study, cemsidomide demonstrated a 53% response rate in heavily pretreated patients, and the MOMENTUM trial aims for at least a 40% response rate for potential accelerated approval.
Feb 11, 2026, 4:30 PM
C4 Therapeutics Discusses Cemsidomide Development and Financial Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics' lead program, cemsidomide, an IKZF1/3 degrader, is entering later-stage clinical development with a Phase 2 MOMENTUM trial starting this quarter and a Phase 1/b combination study with elranatamab (Pfizer) in Q2.
- The company plans to leverage the FDA's new draft guidance on MRD negativity to potentially expedite development and support accelerated approval for cemsidomide, particularly in the MOMENTUM trial and future Phase 3 plans.
- Cemsidomide showed a response rate of up to 53% in heavily pretreated patients, with the single-arm MOMENTUM trial aiming for at least a 40% response rate within 12 months of enrollment to support accelerated approval, with full regulatory endpoints expected into 2028.
- Financing secured in fall 2025 extends the company's cash runway to the end of 2028, with potential for over $200 million in additional funding from warrants to support Phase 3 development.
Feb 11, 2026, 4:30 PM
C4 Therapeutics Outlines Strategic Milestones and Cash Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics plans to initiate the Phase 2 MOMENTUM trial for cemsidomide in Q1 2026 and a Phase 1b trial for cemsidomide in combination with elranatamab in Q2 2026.
- The company anticipates submitting a new drug application for cemsidomide and dexamethasone by year-end 2028 for potential accelerated approval in fourth line or later multiple myeloma.
- C4T's internal discovery strategy aims to deliver up to three investigational new drug applications by year-end 2028, focusing on inflammation, neuro-inflammation, and neuro-degenerative diseases.
- The company reports a cash runway to the end of 2028, providing funding through key value inflection points.
Jan 14, 2026, 12:12 PM
C4 Therapeutics Outlines Strategic Milestones for Cemsidomide and Discovery Pipeline, Projects Cash Runway to End of 2028
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics (C4T) plans to initiate the Phase 2 MOMENTUM trial for cemsidomide in Q1 2026, targeting a new drug application submission by year-end 2028 for potential accelerated approval in relapsed/refractory multiple myeloma.
- A Phase 1b trial of cemsidomide in combination with elranatamab is scheduled to begin in Q2 2026, with a Phase 3 trial planned by early 2028.
- The company's internal discovery strategy aims to deliver up to three investigational new drug applications by year-end 2028, focusing on inflammation, neuro-inflammation, and neuro-degenerative diseases.
- C4T projects a cash runway to the end of 2028, providing funding through these key development milestones.
Jan 14, 2026, 12:00 PM
C4 Therapeutics Provides Update on Clinical Programs and Financial Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics (CCCC) reported positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, in multiple myeloma patients, showing an overall response rate (ORR) of 36% across 72 patients and 53% at the 100 microgram dose, with a median duration of treatment of 9.3 months. The safety profile was differentiated, with no discontinuations due to safety and only 6% dose reductions.
- The cemsidomide study cohort included heavily pre-treated patients, with 100% triple-class exposed and 75% having received prior CAR T or T-cell engager therapy. The company believes this profile is competitive with other treatments like mezigdomide, particularly regarding tolerability.
- C4 Therapeutics has extended its cash runway through the end of 2028, which does not include potential milestone payments of up to $40 million over 2026 and 2027 from collaboration partners. This runway supports data readouts from the Phase 2 MOMENTUM study and the Phase 1b combination study with Elrexfio.
- A decision on advancing the CFT8919 program, an EGFR L858R degrader, is expected by the end of Q1 2026.
Dec 3, 2025, 8:25 PM
C4 Therapeutics Provides Update on Cemsidomide Clinical Development and Financial Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics (CCCC) presented positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, showing an Overall Response Rate (ORR) of 53% at the 100 microgram dose in heavily pre-treated multiple myeloma patients, with a favorable safety profile and 9.3 months median duration of treatment.
- The company plans to meet with the FDA later this month to align on the dose for the next phase of studies for cemsidomide, with enrollment expected to begin early next year. They anticipate a 40% ORR for the single-arm 4L+ study.
- C4 Therapeutics has a cash runway through the end of 2028, which funds data readouts from the Phase 2 MOMENTUM study and the Phase 1b combination study with Elrexfio. This runway does not include potential milestone payments of up to $40 million expected from collaboration partners over 2026 and 2027.
- The company also has an ongoing Phase 1 study for CFT8919, an EGFR L858R degrader, with a decision on advancing the program expected by the end of Q1 2026.
Dec 3, 2025, 8:25 PM
C4 Therapeutics Details Sensitamide Clinical Progress and Commercial Potential
CCCC
New Projects/Investments
Product Launch
Guidance Update
- C4 Therapeutics, a targeted protein degradation company, highlighted its lead program, Sensitamide, an IKZF1/3 degrader for multiple myeloma, which recently demonstrated a best-in-class profile with a 53% response rate in the 100 micrograms cohort in late-line refractory patients.
- The company plans to initiate new Sensitamide studies in early 2026, including a Phase 1B combination study with Pfizer's ELREXFIO and a non-randomized Phase 2 study targeting accelerated approval in late-line patients.
- C4 Therapeutics projects the commercial potential for Sensitamide to be between $2.5 billion and $4 billion, driven by its application in late-line multiple myeloma and in combination with BITEs in earlier treatment lines.
- The company has secured a financial runway through the end of 2028 following a recent financing.
Nov 12, 2025, 1:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more